Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Advanced and recurrent endometrial cancer: State of the art and future perspectives
Francesca Tronconi, Camilla Nero, Elena Giudice, et al.
Critical Reviews in Oncology/Hematology (2022) Vol. 180, pp. 103851-103851
Closed Access | Times Cited: 42

Showing 1-25 of 42 citing articles:

Global burden of gynaecological cancers in 2022 and projections to 2050
Binhua Zhu, Hao Gu, Zhihan Mao, et al.
Journal of Global Health (2024) Vol. 14
Open Access | Times Cited: 14
Identification and validation of the important role of KIF11 in the development and progression of endometrial cancer
Biying Wang, Lunmin Bao, Xiaoduo Li, et al.
Journal of Translational Medicine (2025) Vol. 23, Iss. 1
Open Access | Times Cited: 1
The clinical landscape of antibody-drug conjugates in endometrial cancer
Giovanni Fucá, Ilaria Sabatucci, Mariachiara Paderno, et al.
International Journal of Gynecological Cancer (2024) Vol. 34, Iss. 11, pp. 1795-1804
Closed Access | Times Cited: 5
Novel Molecular Targets in Endometrial Cancer: Mechanisms and Perspectives for Therapy
Pamela Soberanis Pina, Stéphanie Lheureux
Biologics (2024) Vol. Volume 18, pp. 79-93
Open Access | Times Cited: 4
Overall survival and patient-reported outcome results from the placebo-controlled randomized phase III IMagyn050/GOG 3015/ENGOT-OV39 trial of atezolizumab for newly diagnosed stage III/IV ovarian cancer
Sandro Pignata, Michael A. Bookman, Jalid Sehouli, et al.
Gynecologic Oncology (2023) Vol. 177, pp. 20-31
Closed Access | Times Cited: 10
Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
Ji Ren, Jinghe Wang, Yanan Wang, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Inhibition of lanosterol synthase linking with MAPK/JNK signaling pathway suppresses endometrial cancer
Liangjian Ma, Wunan Huang, Xiaolei Liang, et al.
Cell Death Discovery (2025) Vol. 11, Iss. 1
Open Access
WRN dependency in dMMR/MSI-H endometrial cancer: Clinical perspectives of a novel synthetic lethality strategy
Giovanni Fucá, Cristian Dell'Acqua, Beatrice Peruffo, et al.
Gynecologic Oncology (2025) Vol. 195, pp. 12-15
Closed Access
Advancements in Endometrial Cancer Research in 2024
Brigitte Scott, Domenica Lorusso
EMJ Oncology (2025), pp. 2-13
Open Access
Mismatch Repair-Deficient FIGO Stage IA Endometrial Adenocarcinoma With Negative Nodal Biopsy Presenting as Isolated Orbital Metastasis
Steven B Barker, Aditya Ghosh, Christie Taylor, et al.
Cureus (2025)
Open Access
Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells
Ye Yang, Jieyun Zhou, Qiaoying Lv, et al.
Frontiers in Pharmacology (2025) Vol. 16
Open Access
Differential Localization of β-catenin Protein in CTNNB1 Mutant Endometrial Cancers Results in Distinct Transcriptional Profiles
Molly Parrish, Macy L Osborne-Frazier, Russell R. Broaddus, et al.
Modern Pathology (2025), pp. 100791-100791
Closed Access
Comparing survival outcomes between surgical and non-surgical treatments in patients with early-onset endometrial cancer and developing a nomogram to predict survival: a study based on Eastern and Western data sets
Yunfeng Zheng, Ran Hu, Fan Yang, et al.
World Journal of Surgical Oncology (2025) Vol. 23, Iss. 1
Open Access
Licochalcone A induces endoplasmic reticulum stress‐mediated apoptosis of endometrial cancer cells via upregulation of GRP78 expression
Minhua Wu, Yi‐Hsien Hsieh, Chia‐Liang Lin, et al.
Environmental Toxicology (2024) Vol. 39, Iss. 5, pp. 2961-2969
Closed Access | Times Cited: 3
miR-34b-5p suppresses the epithelial-mesenchymal transition and metastasis in endometrial cancer AN3CA cells by targeting ZEB1
Lulu Shi
International Journal of Clinical and Experimental Pathology (2024) Vol. 17, Iss. 4, pp. 137-150
Open Access | Times Cited: 3
Circular RNAs in gynecologic cancers: mechanisms and implications for chemotherapy resistance
Meiying Qin, Chunmei Zhang, Li Yang
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 8
Advancements in Endometrial Cancer Research in 2023
Brigitte Scott
EMJ Oncology (2024), pp. 2-13
Open Access | Times Cited: 2
Hormone Receptor Expression and Activity for Different Tumour Locations in Patients with Advanced and Recurrent Endometrial Carcinoma
Maartje M. W. Luijten, Willem Jan van Weelden, Roy Lalisang, et al.
Cancers (2024) Vol. 16, Iss. 11, pp. 2084-2084
Open Access | Times Cited: 2
Combination of circulating tumor cells, lncRNAs and DNA methylation for the diagnosis of endometrial carcinoma
Hongmei Ding, Juan Wang, Xiaoyu Zhao, et al.
Oncology Letters (2024) Vol. 28, Iss. 5
Open Access | Times Cited: 2
Prognostic Nutritional Index and the Survival of Patients with Endometrial cancer: A Meta-analysis
Li Zhang, Fengliang Wang, Cong Wan, et al.
Reproductive Sciences (2024)
Closed Access | Times Cited: 2
Ipatasertib exhibits anti‑tumorigenic effects and enhances sensitivity to paclitaxel in endometrial cancer in vitro and in vivo
Jillian O’Donnell, Ziyi Zhao, Lindsey Buckingham, et al.
International Journal of Oncology (2023) Vol. 63, Iss. 3
Open Access | Times Cited: 5
Effectiveness and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a systematic review and meta-analysis
Songfei Han, Cuishan Guo, Zixuan Song, et al.
Frontiers in Pharmacology (2023) Vol. 14
Open Access | Times Cited: 4
Efficacy and safety of lenvatinib plus pembrolizumab in patients with advanced and recurrent endometrial cancer: a systematic review and meta-analysis
Guangwei Yan, Yanmin Du, Huanhuan Zhang, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
Association Between Intermediate End Points, Progression-free Survival, and Overall Survival in First-line Advanced or Recurrent Endometrial Cancer
Jamie Garside, Qin Shen, Bernd Westermayer, et al.
Clinical Therapeutics (2023) Vol. 45, Iss. 10, pp. 983-990
Open Access | Times Cited: 2
Recent Developments in Endometrial Cancer Research Presented at the Society of Gynecologic Oncology (SGO) Annual Meeting 2023: Interviews with Two Key Opinion Leaders
Brigitte Scott
EMJ Oncology (2023), pp. 2-10
Open Access | Times Cited: 2
Page 1 - Next Page

Scroll to top